Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

NCT05710666 · clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
11
Enrollment
NETWORK
Sponsor class

Conditions

Interventions

Sponsor

Cancer Trials Ireland